全文获取类型
收费全文 | 39552篇 |
免费 | 3058篇 |
国内免费 | 1006篇 |
专业分类
耳鼻咽喉 | 470篇 |
儿科学 | 946篇 |
妇产科学 | 239篇 |
基础医学 | 4361篇 |
口腔科学 | 2662篇 |
临床医学 | 2621篇 |
内科学 | 3735篇 |
皮肤病学 | 191篇 |
神经病学 | 809篇 |
特种医学 | 2479篇 |
外科学 | 15737篇 |
综合类 | 4293篇 |
现状与发展 | 2篇 |
预防医学 | 1050篇 |
眼科学 | 347篇 |
药学 | 1448篇 |
13篇 | |
中国医学 | 689篇 |
肿瘤学 | 1524篇 |
出版年
2023年 | 425篇 |
2022年 | 678篇 |
2021年 | 1060篇 |
2020年 | 1014篇 |
2019年 | 1062篇 |
2018年 | 1271篇 |
2017年 | 1098篇 |
2016年 | 1299篇 |
2015年 | 1389篇 |
2014年 | 2357篇 |
2013年 | 2477篇 |
2012年 | 1974篇 |
2011年 | 2346篇 |
2010年 | 1904篇 |
2009年 | 2126篇 |
2008年 | 2123篇 |
2007年 | 2112篇 |
2006年 | 2034篇 |
2005年 | 2008篇 |
2004年 | 1669篇 |
2003年 | 1422篇 |
2002年 | 1080篇 |
2001年 | 983篇 |
2000年 | 953篇 |
1999年 | 805篇 |
1998年 | 673篇 |
1997年 | 640篇 |
1996年 | 492篇 |
1995年 | 486篇 |
1994年 | 434篇 |
1993年 | 356篇 |
1992年 | 329篇 |
1991年 | 280篇 |
1990年 | 237篇 |
1989年 | 208篇 |
1988年 | 196篇 |
1987年 | 165篇 |
1986年 | 181篇 |
1985年 | 165篇 |
1984年 | 132篇 |
1983年 | 72篇 |
1982年 | 130篇 |
1981年 | 105篇 |
1980年 | 102篇 |
1979年 | 111篇 |
1978年 | 89篇 |
1977年 | 75篇 |
1976年 | 57篇 |
1973年 | 40篇 |
1969年 | 31篇 |
排序方式: 共有10000条查询结果,搜索用时 375 毫秒
21.
目的:分析比较"F"形空心钉与传统倒三角3枚平行螺钉内固定治疗青壮年Pauwels Ⅲ型股骨颈骨折的临床疗效。方法:2017年1月至2020年1月收治Pauwels Ⅲ型股骨颈骨折患者38例,根据置入钉方式的不同将其分为两组,其中A组18例,采用"F"形空心钉固定,男12例,女6例,年龄37~55岁,受伤至手术时间1~3 d。B组20例,采用传统倒三角3枚平行拉力螺钉固定,男12例,女8例,年龄35~55岁,受伤至手术时间为1~3 d。比较两组患者骨折不愈合,股骨头坏死,股骨颈短缩,空心螺钉退出情况,髋关节功能Harris评分,疼痛视觉模拟评分(visual analogue scale,VAS)。结果:所有患者获得随访,时间为15~31个月。两组患者在骨折不愈合,股骨颈短缩,股骨头坏死方面差异无统计学意义(P>0.05);两组患者在螺钉退出方面差异有统计学意义(P<0.05)。两组患者术后12个月时髋关节Harris评分及VAS评分差异均无统计学差异(P>0.05)。结论:"F"形与传统倒三角3枚平行空心钉内固定治疗青壮年Pauwels Ⅲ型股骨颈骨折中短期疗效相似,但"F"形空心钉退钉率较低。 相似文献
22.
《Biomaterials》2015
In normal tissue repair, macrophages exhibit a pro-inflammatory phenotype (M1) at early stages and a pro-healing phenotype (M2) at later stages. We have previously shown that M1 macrophages initiate angiogenesis while M2 macrophages promote vessel maturation. Therefore, we reasoned that scaffolds that promote sequential M1 and M2 polarization of infiltrating macrophages should result in enhanced angiogenesis and healing. To this end, we first analyzed the in vitro kinetics of macrophage phenotype switch using flow cytometry, gene expression, and cytokine secretion analysis. Then, we designed scaffolds for bone regeneration based on modifications of decellularized bone for a short release of interferon-gamma (IFNg) to promote the M1 phenotype, followed by a more sustained release of interleukin-4 (IL4) to promote the M2 phenotype. To achieve this sequential release profile, IFNg was physically adsorbed onto the scaffolds, while IL4 was attached via biotin-streptavidin binding. Interestingly, despite the strong interactions between biotin and streptavidin, release studies showed that biotinylated IL4 was released over 6 days. These scaffolds promoted sequential M1 and M2 polarization of primary human macrophages as measured by gene expression of ten M1 and M2 markers and secretion of four cytokines, although the overlapping phases of IFNg and IL4 release tempered polarization to some extent. Murine subcutaneous implantation model showed increased vascularization in scaffolds releasing IFNg compared to controls. This study demonstrates that scaffolds for tissue engineering can be designed to harness the angiogenic behavior of host macrophages towards scaffold vascularization. 相似文献
23.
《Clinical Lymphoma, Myeloma & Leukemia》2020,20(7):415-421
Myelofibrosis (MF) is a BCR-ABL1− myeloproliferative neoplasm that arises from hematopoietic stem and progenitor cells frequently harboring a somatic driver mutation in 1 of 3 genes: JAK2, CALR, or MPL. The pathologic features of this hematologic malignancy include myeloproliferation, diffuse bone marrow fibrosis, and overactivation of the JAK-STAT pathway, resulting in enhanced inflammatory cytokine release. The common clinical manifestations of MF include systemic symptoms, abnormal peripheral blood count levels, and splenomegaly. However, it has become increasingly appreciated that significant clinical heterogeneity exists among patients with MF. Two distinct MF clinical phenotypes include the myeloproliferative and myelodepletive phenotype, with peripheral blood counts being the main discerning feature. Patients with the myeloproliferative phenotype will present with elevated peripheral blood counts and often experience significant constitutional symptoms and progressive splenomegaly. In contrast, patients with the myelodepletive phenotype will have low peripheral blood counts and will frequently require transfusion support. Current frontline therapies for MF, include ruxolitinib and fedratinib, which can exacerbate cytopenias and thereby pose an impediment to effective treatment of the myelodepletive patient. The present review discusses the clinical and prognostic implications of the myelodepletive phenotype and the therapeutic options and limitations for this subset of patients, representing an unmet clinical need. 相似文献
24.
《Journal of vascular and interventional radiology : JVIR》2020,31(4):630-634
PurposeTo retrospectively evaluate the safety and effectiveness of the Covera stent graft (SG) for the treatment of dysfunctional or thrombosed arteriovenous grafts (AVGs).Materials and MethodsWithin 29 months (February 2016–August 2018), 79 patients underwent Covera SG placement in the authors’ department for the treatment of dysfunctional AVGs. Data were available for 64 patients who underwent 64 procedures, using 64 devices. Minimum follow-up was 6 months, unless reintervention occurred. Mean follow-up was 277 days (6–923 days). Treatment characteristics were 51 cases with venous-graft anastomosis (VGA) stenosis (79.7%), 13 cases of puncture zone stenosis (20.3%), 14 cases of in SG stenosis (21.9%), 8 cases of pseudoaneurysm treatment (12.5%) (1 treatment area might have had more than 1 characteristic). Thirty-six patients presented with thrombosis (56.2%), and 31 of 64 case were de novo treatment areas (48.4%). Primary outcome measurements were technical success and post-intervention primary patency (PIPP) at 6 months, whereas secondary outcome measurements included factors influencing primary outcome.ResultsTechnical success was 100%. Median PIPP was 336 days, and 73.6% of treatment areas were patent at 6 months. There were no significant differences in terms of PIPP when de novo treatment areas were compared with restenotic areas (519 vs. 320 days, respectively; P = .1); patients who presented with versus those who presented without thrombosis (320 vs. 583 days, respectively; P = .07); puncture zone stenosis or elsewhere (329 vs. 686 days, respectively; P = .52); and VGA stenosis or elsewhere (336 vs. 335 days, respectively; P = .9).ConclusionsUse of the Covera SG for AVG treatment was safe and effective in every type of treatment area presented in this retrospective analysis. 相似文献
25.
Changes in Right Ventricular Shape and Deformation Following Coronary Artery Bypass Surgery—Insights from Echocardiography with Strain Rate and Magnetic Resonance Imaging 下载免费PDF全文
26.
27.
28.
29.
目的 探讨保留足趾的自体复合第2足趾关节移植治疗手指关节炎的临床疗效.方法 2016年2月至2018年6月,共收治创伤性手指关节炎9例,其中男7例,女2例;年龄19~53岁,平均31.7岁;示指3例,中指6例;掌指关节(MP)关节炎4例,近侧指骨间关节(PIP)关节炎5例;均为创伤后继发的手指关节炎.采用游离带血供的自体复合第2足趾跖趾或趾骨间关节移植进行治疗,同时将受区废弃关节(7例)或切取自体髂骨移植(2例)修复供区骨缺损保留足趾长度,供区创面均直接关闭.术后观察手指和足趾骨折愈合情况、外形、移植关节活动度(ROM)、术后供区愈合情况和行走功能及相关并发症.结果 本组术后9例移植关节全部成活,1例足部供区行髂骨植骨微型钢板固定,术后1周伤口不愈合,考虑为内固定物排异反应,予拆除钢板改克氏针交叉固定,2周后创口顺利愈合.术后随访6~30个月,平均16.3个月.手指骨折平均愈合时间7~10周,平均8.3周,手指外观及功能良好.移植后的MP活动度为50°~75°,平均65.3°,PIP活动度为10°~85°,平均60.6°.根据中华医学会手外科学分会上肢部分功能评定试用标准评价手指功能:优5例,良3例,可1例,优良率为88.9%.足趾骨折平均愈合时间9~12周,平均10.2周,所有患者足趾外形良好,行走功能正常.2例取髂骨患者供区仅残留一条线形瘢痕,无疼痛、麻木等不适.结论 游离带血供的自体复合第2足趾关节移植治疗手指关节炎,同时应用受区废弃关节或切取自体髂骨移植修复供区骨缺损保留足趾,不仅能恢复手指关节的正常结构,使关节具有良好的功能,而且能保留足趾外形与功能,减少供区损伤,具有良好的治疗效果. 相似文献